menu
Industrial platform
Orano Med has developed a patented chemical process allowing production of 212Pb on a large scale and at a reasonable cost
Large-scale production of 212Pb
Development of TAT has long been hindered by a lack of supply of alpha emitting radioisotopes meeting three important criteria: purity meeting radiopharmaceutical standards, reliable production capacity sufficient to meet global needs, and economic competitiveness.
With a unique and proprietary source of raw material (Thorium 232), Orano Med has developed a patented chemical process allowing production of 212Pb on a large scale and at a reasonable cost.
Facilities that are unique in the world
In order to be able to produce and distribute 212Pb-conjugated drugs, Orano Med has equipped itself with facilities which are unique worldwide:
- In France at Bessines-sur-Gartempe, the Laboratoire Maurice Tubiana (LMT) produces the precursors of 212Pb (Radium 228 and Thorium 228) for the manufacturing of doses of 212Pb for preclinical research and clinical trials;
- In the USA at Plano in Texas, the Domestic Distribution & Purification Unit (DDPU) produces 212Pb for North America and drugs for clinical trials in progress in accordance with GMP standards;
- In the USA at Brownsburg in Indiana, the first Alpha Therapy Laboratory (ATLab) is currently under construction. As of 2024, it will commence the large-scale production of vectorized internal radiotherapy treatments and their distribution in North America. The construction of other ATLabs will be launched shortly to cover global needs.
- In 2011, Orano Med also acquired Macrocyclics which has globally-recognized expertise in the production and development of chelating agents for nuclear medicine.